Journals Cancer Immunology, Immunothera...

Cancer Immunology, Immunotherapy : CII
A-M Arendt, F Heubach, C P Maier, S Giardino, G Jung, E Kowalewski, A Rabsteyn, G Amorelli, C Seitz, P Schlegel, R Handgretinger, P Lang
We investigated whether T cell-recruiting bispecific anti-CD3/GD2 antibody NG-CU might be an alternative to therapeutic anti-GD2 monoclonal antibody (mAb) ch14.18, mediating complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) through natural killer (NK) cells for immunotherapy in high-risk/relapsed neuroblastoma after autologous/allogeneic stem cell transplantation (auto/alloSCT). Different antibody concentrations and effector-to-target ratios (E:T) were evaluated using xCELLigence RTCA system, peripheral blood mononuclear cells (PBMCs) (healthy donors and patients after alloSCT), and neuroblastoma cell lines (LS/LAN-1)...
September 24, 2023: Cancer Immunology, Immunotherapy: CII
Juan A Hernández-Aceves, Jacquelynne Cervantes-Torres, Diana Torres-García, Francisco J Zuñiga-Flores, Osiris J Patiño-Chávez, Jorge A Peña Agudelo, José Eduardo Aguayo-Flores, Yonathan Garfias, Laura Montero-León, Laura Romero-Romero, Armando Pérez-Torres, Gladis Fragoso, Edda Sciutto
Breast cancer is the leading malignancy in women worldwide, both in terms of incidence and mortality. Triple-negative breast cancer (TNBC) is the type with the worst clinical outcomes and with fewer therapeutic options than other types of breast cancer. GK-1 is a peptide that in the experimental model of the metastatic 4T1 breast cancer has demonstrated anti-tumor and anti-metastatic properties. Herein, GK-1 (5 mg/kg, i.v.) weekly administrated not only decreases tumor growth and the number of lung macro-metastases but also lung and lymph nodes micro-metastases...
September 22, 2023: Cancer Immunology, Immunotherapy: CII
Lisa May Ling Tachiki, Daniel S Hippe, Karly Williams Silva, Evan Thomas Hall, William McCamy, Dane Fritzsche, Andrea Perdue, Julia Majovski, Thomas Pulliam, Daniel A Goldstein, Joshua Veatch, Joel Ho, Paul T Nghiem, John A Thompson, Shailender Bhatia
BACKGROUND: Optimal duration of treatment (DoT) with immune checkpoint inhibitors (ICI) in metastatic cancers remains unclear. Many patients, especially those without radiologic complete remission, develop progressive disease after ICI discontinuation. Extending DoT with ICI may potentially improve efficacy outcomes but presents major logistical and cost challenges with standard frequency dosing (SFD). Receptor occupancy data supports reduced frequency dosing (RFD) of anti-PD-1 antibodies, which may represent a more practical and economically viable option to extend DoT...
September 21, 2023: Cancer Immunology, Immunotherapy: CII
Peipei Li, Fangchao Li, Yanfei Zhang, Xiaoyang Yu, Jingjing Li
Tumor-infiltrating T cells are promising drug targets to modulate the tumor microenvironment. However, tumor-infiltrating T lymphocytes, as central targets of cancer immunotherapy, show considerable heterogeneity and dynamics across tumor microenvironments and cancer types that may fundamentally influence cancer growth, metastasis, relapse, and response to clinical drugs. The T cell heterogeneity not only refers to the composition of subpopulations but also divergent metabolic states of T cells. Comparing to the diversity of tumor-infiltrating T cell compositions that have been well recognized, the metabolic diversity of T cells deserves more attention for precision immunotherapy...
September 21, 2023: Cancer Immunology, Immunotherapy: CII
Wei-Wei Zheng, Hang Zhou, Ping Li, Shi-Guang Ye, Tuersunayi Abudureheman, Li-Ting Yang, Kai Qing, Ai-Bin Liang, Kai-Ming Chen, Cai-Wen Duan
CD19 CAR-T (chimeric antigen receptor-T) cell immunotherapy achieves a remission rate of approximately 70% in recurrent and refractory lymphoma treatment. However, the loss or reduction of CD19 antigen on the surface of lymphoma cells results in the escape of tumor cells from the immune killing of CD19 CAR-T cells (CAR19-T). Therefore, novel therapeutic strategies are urgently required. In this study, an anti-CD79b/CD3 bispecific antibody (BV28-OKT3) was constructed and combined with CAR19-T cells for B-cell lymphoma treatment...
September 14, 2023: Cancer Immunology, Immunotherapy: CII
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, Yohei Okada, Francesco Massari, Georgia Anguera Palacios, Michele Dionese, Sarah Scagliarini, Thomas Büttner, Giuseppe Fornarini, Zin W Myint, Luca Galli, Vinicius Carrera Souza, Renate Pichler, Ugo De Giorgi, María Natalia Gandur Quiroga, Danielle Gilbert, Lazar Popovic, Enrique Grande, Giulia Mammone, Rossana Berardi, Simon J Crabb, Javier Molina-Cerrillo, Marcelo Freitas, Murilo Luz, Roberto Iacovelli, Fabio Calabrò, Deniz Tural, Francesco Atzori, Zsófia Küronya, Rita Chiari, Saul Campos, Orazio Caffo, André P Fay, Jakub Kucharz, Paolo Andrea Zucali, José Augusto Rinck, Annalisa Zeppellini, Diogo Assed Bastos, Gaetano Aurilio, Augusto Mota, Karine Trindade, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Nuno Vau, Patrizia Giannatempo, Allan Barillas, Fernando Sabino Marques Monteiro, Breno Dauster, Carlo Cattrini, Lucas Nogueira, Roni de Carvalho Fernandes, Emmanuel Seront, Luís Garcia Aceituno, Francesco Grillone, Hernan Javier Cutuli, Mauricio Fernandez, Maria Bassanelli, Giandomenico Roviello, Halima Abahssain, Giuseppe Procopio, Michele Milella, Jindrich Kopecky, Angelo Martignetti, Carlo Messina, Manuel Caitano, Eva Inman, Ravindran Kanesvaran, Daniel Herchenhorn, Daniele Santini, Ray Manneh, Renato Bisonni, Roubini Zakopoulou, Alessandra Mosca, Franco Morelli, Fernando Maluf, Andrey Soares, Fernando Nunes, Alvaro Pinto, Anca Zgura, Lorena Incorvaia, Jawaher Ansari, Ignacio Ortego Zabalza, Johannes Landmesser, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Nicola Battelli, Camillo Porta, Joaquim Bellmunt, Matteo Santoni
BACKGROUND: Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of proton pump inhibitors (PPI), statins, or metformin on outcome of patients with metastatic urothelial cancer (mUC) receiving second-line pembrolizumab. METHODS: We collected data from the hospital medical records of patients with mUC treated with pembrolizumab as second-line therapy at 87 institutions from 22 countries...
September 7, 2023: Cancer Immunology, Immunotherapy: CII
Zhengfeng Zhang, Dazhen Wang, Jianji Zhang, Yuli Ruan, Lu Zhao, Liu Yang, Ze Liu, Lei Yang, Changjie Lou
OBJECTIVE: To analyze the effectiveness of combining immune checkpoint inhibitors (ICIs) with first-line therapy in patients with advanced biliary tract cancer (BTC) and explore the biomarkers affecting the prognosis of immunotherapy, to construct a nomogram for the prediction of survival. METHODS: A retrospective study was conducted to include a total of 209 patients with advanced BTC treated in the first line from 2018 to 2022, divided into a combination therapy group (n = 129) and a chemotherapy-only group (n = 80) according to whether ICIs were applied in combination...
September 5, 2023: Cancer Immunology, Immunotherapy: CII
Kento Kawasaki, Kazuhiro Noma, Takuya Kato, Toshiaki Ohara, Shunsuke Tanabe, Yasushige Takeda, Hijiri Matsumoto, Seitaro Nishimura, Tomoyoshi Kunitomo, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Naoaki Maeda, Satoru Kikuchi, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara
The programmed cell death 1 protein (PD-1)/programmed cell death ligand 1 (PD-L1) axis plays a crucial role in tumor immunosuppression, while the cancer-associated fibroblasts (CAFs) have various tumor-promoting functions. To determine the advantage of immunotherapy, the relationship between the cancer cells and the CAFs was evaluated in terms of the PD-1/PD-L1 axis. Overall, 140 cases of esophageal cancer underwent an immunohistochemical analysis of the PD-L1 expression and its association with the expression of the α smooth muscle actin, fibroblast activation protein, CD8, and forkhead box P3 (FoxP3) positive cells...
September 5, 2023: Cancer Immunology, Immunotherapy: CII
Emanuele Vita, Alessio Stefani, Geny Piro, Luca Mastrantoni, Marco Cintoni, Giuseppe Cicchetti, Ileana Sparagna, Federico Monaca, Guido Horn, Jacopo Russo, Diletta Barone, Mariantonietta Di Salvatore, Rocco Trisolini, Filippo Lococo, Ciro Mazzarella, Alessandra Cancellieri, Carmine Carbone, Anna Rita Larici, Maria Cristina Mele, Sara Pilotto, Michele Milella, Giampaolo Tortora, Emilio Bria
BACKGROUND: Only few ES-SCLC patients experience long-term survival benefit by maintenance IT. Adipokines-induced metabolic meta-inflammation has been related to enhanced responsiveness to IT in obese patients; however, their prognostic role in SCLC is currently controversial. METHODS: Pre-treatment CT scan was used for determining distribution of abdominal adiposity, and blood samples were collected at fasting for measuring glycemia, insulin, ghrelin, leptin and adipokines (TNF-α, IFN-γ, IL-6 and MCP-1)...
September 5, 2023: Cancer Immunology, Immunotherapy: CII
Chunxiao Chang, Yanqing Pei, Chuangnian Zhang, Wenyu Zhang, Yibo Qin, Shengbin Shi
Hepatocellular carcinoma (HCC), a prevalent cause of cancer-related deaths, is insensitive to traditional treatments. At different time intervals, the combined antitumor effects of DC-TEX and the programmed death protein 1 (PD-1) antibody (Ab) have not been investigated. In this study, HCC models were established and treated at different time intervals with DC-TEX alone or in combination with PD-1 Ab. In addition, we developed an orthotopic HCC model in BALB/c nude mice and restored T cells. Results demonstrated that the PD-1 + CD8 + T-cell population also increased significantly after DC-TEX treatment, in addition to the increased number of CD8 + T cells...
September 4, 2023: Cancer Immunology, Immunotherapy: CII
Tavus Atajanova, Md Mahfuzur Rahman, David J Konieczkowski, Zachary S Morris
Radiation is commonly used as a treatment intended to cure or palliate cancer patients. Despite remarkable advances in the precision of radiotherapy delivery, even the most advanced forms inevitably expose some healthy tissues surrounding the target site to radiation. On rare occasions, this results in the development of radiation-associated secondary malignancies (RASM). RASM are typically high-grade and carry a poorer prognosis than their non-radiated counterparts. RASM are characterized by a high mutation burden, increased T cell infiltration, and a microenvironment that bears unique inflammatory signatures of prior radiation, including increased expression of various cytokines (e...
September 2, 2023: Cancer Immunology, Immunotherapy: CII
Koji Teramoto, Tomoyuki Igarashi, Yoko Kataoka, Mitsuaki Ishida, Jun Hanaoka, Hidetoshi Sumimoto, Yataro Daigo
Programmed cell death-ligand 1 (PD-L1) on tumor cells can be degraded to soluble form (sPD-L1) and enter circulation, however, the clinical significances of sPD-L1 in peripheral blood remains to be elucidated in non-small-cell lung cancer (NSCLC). We monitored plasma sPD-L1 levels during perioperative periods and evaluated PD-L1-positive cells in tumor tissues in patients with operable NSCLC. Then the correlation between preoperative plasma sPD-L1 levels and relapse-free survival (RFS) was analyzed retrospectively...
August 30, 2023: Cancer Immunology, Immunotherapy: CII
Navid Sobhani, Giuseppina Mondani, Giandomenico Roviello, Martina Catalano, Marianna Sirico, Alberto D'Angelo, Bruna Scaggiante, Daniele Generali
Since 2019, the world has been experiencing an outbreak of a novel beta-coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV)-2. The worldwide spread of this virus has been a severe challenge for public health, and the World Health Organization declared the outbreak a public health emergency of international concern. As of June 8, 2023, the virus' rapid spread had caused over 767 million infections and more than 6.94 million deaths worldwide. Unlike previous SARS-CoV-1 and Middle East respiratory syndrome coronavirus outbreaks, the COVID-19 outbreak has led to a high death rate in infected patients; this has been caused by multiorgan failure, which might be due to the widespread presence of angiotensin-converting enzyme 2 (ACE2) receptors-functional receptors of SARS-CoV-2-in multiple organs...
August 29, 2023: Cancer Immunology, Immunotherapy: CII
Binyu Song, Yixuan Peng, Yu Zheng, Yuhan Zhu, Wei Liu, Kai Wang, Zhiwei Cui, Baoqiang Song
BACKGROUND: The involvement of ferroptosis in the pathogenesis and progression of various cancers has been well established. However, limited studies have investigated the role of ferroptosis-mediated tumor microenvironment (TME) in skin cutaneous melanoma (SKCM). METHODS: By leveraging single-cell RNA sequencing data, the nonnegative matrix factorization (NMF) approach was employed to comprehensively characterize and identify distinct gene signatures within ferroptosis-associated TME cell clusters...
August 28, 2023: Cancer Immunology, Immunotherapy: CII
Melissa Bersanelli, Alessio Cortellini, Alessandro Leonetti, Alessandro Parisi, Marcello Tiseo, Paola Bordi, Maria Michiara, Simona Bui, Agnese Cosenza, Leonarda Ferri, Giulia Claire Giudice, Irene Testi, Elena Rapacchi, Roberta Camisa, Bruno Vincenzi, Giuseppe Caruso, Antonio Natale Rauti, Federica Arturi, Marco Tucci, Valentina Santo, Valentina Ricozzi, Vanessa Burtet, Paolo Sgargi, Renata Todeschini, Fable Zustovich, Luigia Stefania Stucci, Daniele Santini, Sebastiano Buti
BACKGROUND: Hypovitaminosis D can have a negative prognostic impact in patients with cancer. Vitamin D has a demonstrated role in T-cell-mediated immune activation. We hypothesized that systematic vitamin D repletion could impact clinical outcomes in patients with cancer receiving immune-checkpoint inhibitors (ICIs). METHODS: We planned a prospective observational study (PROVIDENCE) to assess serum vitamin D levels in patients with advanced cancer receiving ICIs (cohort 1 at treatment initiation, cohort 2 during treatment) and the impact of systematic repletion on survival and toxicity outcomes...
August 28, 2023: Cancer Immunology, Immunotherapy: CII
Shinsuke Ogusu, Yuhei Harutani, Takehiro Tozuka, Ryota Saito, Junji Koyama, Hiroaki Sakamoto, Tomoaki Sonoda, Yuko Tsuchiya-Kawano, Tomohiro Oba, Keita Kudo, Hiroshi Gyotoku, Katsumi Nakatomi, Ryo Ariyasu
BACKGROUND: Evidence for use of second-line immunosuppressants for immune-related adverse events (irAEs) is inadequate. Therefore, a multicenter analysis should assess the efficacy of second-line immunosuppressants for severe irAEs associated with different malignant diseases. METHODS: This descriptive study aims to investigate the effects of second-line immunosuppressants on corticosteroid-refractory irAEs in patients with lung cancer. We analyzed the effects of second-line immunosuppressants on underlying lung cancer and associated adverse effects...
August 28, 2023: Cancer Immunology, Immunotherapy: CII
Sung Soo Mun, Jeremy Meyerberg, Leila Peraro, Tatyana Korontsvit, Thomas Gardner, Manish Malviya, Chrisann Kyi, Roisin E O'Cearbhaill, Cheng Liu, Tao Dao, David A Scheinberg
Epithelial ovarian cancer is the most lethal of gynecological cancers. The therapeutic efficacy of chimeric antigen receptor (CAR) T cell directed against single antigens is limited by the heterogeneous target antigen expression in epithelial ovarian tumors. To overcome this limitation, we describe an engineered cell with both dual targeting and orthogonal cytotoxic modalities directed against two tumor antigens that are highly expressed on ovarian cancer cells: cell surface Muc16 and intracellular WT1. Muc16-specific CAR T cells (4H11) were engineered to secrete a bispecific T cell engager (BiTE) constructed from a TCR mimic antibody (ESK1) reactive with the WT1-derived epitope RMFPNAPYL (RMF) presented by HLA-A2 molecules...
August 27, 2023: Cancer Immunology, Immunotherapy: CII
Sharif M Ridwan, Rose Emlein, Asghar Mesbahi, Andrew Annabi, James F Hainfeld, Henry M Smilowitz
Radiation therapy (RT) treats approximately half of all cancers and most brain cancers. RT is variably effective at inducing a dormant tumor state i.e. the time between RT and clinical recurrence of tumor growth. Interventions that significantly lengthen tumor dormancy would improve long-term outcomes. Inflammation can promote the escape of experimental tumors from metastatic dormancy in the lung. Previously we showed intracerebral B16F10 melanoma dormancy varied with RT dose; 20.5 Gy induced dormancy lasted ~ 2 to 4 weeks-sufficient time to study escape from dormancy...
August 23, 2023: Cancer Immunology, Immunotherapy: CII
Sarah Schober, Jennifer M Rottenberger, Johannes Hilz, Evi Schmid, Martin Ebinger, Tobias Feuchtinger, Rupert Handgretinger, Peter Lang, Manon Queudeville
Immune milieus play an important role in various types of cancer. The present study focuses on the effect of Th1 cytokines on pediatric acute lymphoblastic leukemia (ALL). The reaction of ALL cell lines and patient-derived xenografts (PDX) to the most important Th1 cytokines TNF-α (tumor necrosis factor alpha) and IFN-γ (interferon gamma) is analyzed and correlated with the respective cytokine receptors and the intracellular signaling molecules. ALL cell lines and ALL PDX display a great heterogeneity in cell death after incubation with TNF-α and IFN-γ...
August 23, 2023: Cancer Immunology, Immunotherapy: CII
Yakun Zhang, Yue Sun, Jing Gan, Hanxiao Zhou, Shuang Guo, Xinyue Wang, Caiyu Zhang, Wen Zheng, Xiaoxi Zhao, Yunpeng Zhang, Shangwei Ning, Xia Li
Immunosenescence has been demonstrated to play an important role in tumor progression. However, there is lacking comprehensive analyses of immunosenescence-related pathways. Meanwhile, the sex disparities of immunosenescence in cancer are still poorly understood. In this study, we analyzed the multi-omics data of 12,836 tumor samples, including genomics, transcriptomics, epigenomics, proteomics, and metabolomics. We systematically identified immunosenescence pathways that were disordered across cancer types...
August 22, 2023: Cancer Immunology, Immunotherapy: CII
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.